Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biohaven Ltd. stock logo
BHVN
Biohaven
$9.45
-0.1%
$9.43
$7.48
$18.57
$1.42B1.321.94 million shs1.44 million shs
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.35
$0.37
$0.33
$0.82
$372.15M0.4578,749 shs341,279 shs
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
$0.29
-7.0%
$0.29
$0.00
$0.08
$1.44B10.91.01 million shs115,457 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$28.89
$22.92
$3.61
$32.37
$1.41B1.58920,799 shs364,372 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biohaven Ltd. stock logo
BHVN
Biohaven
0.00%+11.17%-4.25%-20.19%-39.72%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00%+5.27%-4.85%-14.69%-34.74%
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
0.00%0.00%0.00%0.00%+201.25%
Urogen Pharma stock logo
URGN
Urogen Pharma
0.00%+1.08%+19.83%+39.23%+589.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biohaven Ltd. stock logo
BHVN
Biohaven
$9.45
-0.1%
$9.43
$7.48
$18.57
$1.42B1.321.94 million shs1.44 million shs
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.35
$0.37
$0.33
$0.82
$372.15M0.4578,749 shs341,279 shs
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
$0.29
-7.0%
$0.29
$0.00
$0.08
$1.44B10.91.01 million shs115,457 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$28.89
$22.92
$3.61
$32.37
$1.41B1.58920,799 shs364,372 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biohaven Ltd. stock logo
BHVN
Biohaven
0.00%+11.17%-4.25%-20.19%-39.72%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00%+5.27%-4.85%-14.69%-34.74%
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
0.00%0.00%0.00%0.00%+201.25%
Urogen Pharma stock logo
URGN
Urogen Pharma
0.00%+1.08%+19.83%+39.23%+589.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biohaven Ltd. stock logo
BHVN
Biohaven
2.71
Moderate Buy$22.27135.75% Upside
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
0.00
N/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
2.80
Moderate Buy$36.6726.92% Upside

Current Analyst Ratings Breakdown

Latest ELTP, URGN, TRUU, and BHVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/18/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Reiterated RatingBuy$45.00
5/13/2026
Biohaven Ltd. stock logo
BHVN
Biohaven
Lower Price TargetOverweight$21.00 ➝ $18.00
5/11/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Boost Price TargetBuy$40.00 ➝ $45.00
5/11/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Initiated CoverageBuy$43.00
5/7/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Boost Price TargetOutperform$34.00 ➝ $40.00
5/5/2026
Biohaven Ltd. stock logo
BHVN
Biohaven
Lower Price TargetOutperform$23.00 ➝ $22.00
4/24/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
UpgradeStrong-Buy
4/20/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Reiterated RatingSell (D-)
4/13/2026
Biohaven Ltd. stock logo
BHVN
Biohaven
Initiated CoverageBuy$21.00
4/10/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Initiated CoverageBuy$40.00
4/2/2026
Biohaven Ltd. stock logo
BHVN
Biohaven
Boost Price TargetBuy$14.00 ➝ $17.00
(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$0.86 per shareN/A
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M4.43$0.02 per share20.14$0.05 per share6.91
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
$1.95M739.78N/AN/A($0.03) per share-9.67
Urogen Pharma stock logo
URGN
Urogen Pharma
$109.79M12.82N/AN/A($2.55) per share-11.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biohaven Ltd. stock logo
BHVN
Biohaven
-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-$4.32M$0.0311.52N/AN/A30.98%47.93%25.81%N/A
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
-$3.88M$0.0129.01N/AN/A-255.80%N/A-165.86%N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
-$153.49M-$2.75N/A20.64N/A-94.83%N/A-62.85%8/6/2026 (Estimated)

Latest ELTP, URGN, TRUU, and BHVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 million
5/4/2026Q1 2026
Biohaven Ltd. stock logo
BHVN
Biohaven
-$0.86-$0.88-$0.02-$0.88$0.27 millionN/A
3/2/2026Q4 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.22-$1.21+$0.01-$1.21$3.86 millionN/A
3/2/2026Q4 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.66-$0.54+$0.12-$0.54$39.92 million$37.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biohaven Ltd. stock logo
BHVN
Biohaven
1.87
7.41
7.41
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.05
7.34
5.44
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
N/A
0.01
N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
4.69
4.28

Institutional Ownership

CompanyInstitutional Ownership
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%

Insider Ownership

CompanyInsider Ownership
Biohaven Ltd. stock logo
BHVN
Biohaven
13.80%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
18.18%
Urogen Pharma stock logo
URGN
Urogen Pharma
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239150.56 million129.78 millionOptionable
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.08 billion921.81 millionNot Optionable
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
404.97 billionN/ANot Optionable
Urogen Pharma stock logo
URGN
Urogen Pharma
20048.72 million46.43 millionOptionable

Recent News About These Companies

URGN Share News Today
Urogen Pharma Q1 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biohaven stock logo

Biohaven NYSE:BHVN

$9.44 -0.01 (-0.05%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$9.38 -0.06 (-0.69%)
As of 05/22/2026 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.35 0.00 (0.00%)
As of 05/22/2026 03:57 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

True Drinks stock logo

True Drinks OTCMKTS:TRUU

$0.29 -0.02 (-7.02%)
As of 02/19/2026

True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$28.89 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$28.90 +0.01 (+0.03%)
As of 05/22/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.